Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4

[1]  A. Markham.  Envafolimab: First Approval , 2022, Drugs.

[2]  Wen-quan Wang,et al.  Histone deacetylases: A novel class of therapeutic targets for pancreatic cancer. , 2022, Biochimica et biophysica acta. Reviews on cancer.

[3]  Jianwei Zhu,et al.  A Novel Bispecific Antibody Targeting CD3 and Lewis Y with Potent Therapeutic Efficacy against Gastric Cancer , 2021, Biomedicines.

[4]  L. Shen,et al.  Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors , 2021, Journal of Hematology & Oncology.

[5]  Jianwei Zhu,et al.  A Rational Designed Novel Bispecific Antibody for the Treatment of GBM , 2021, Biomedicines.

[6]  K. Papadopoulos,et al.  First-in-Human Phase I Study of Envafolimab, a Novel Subcutaneous Single-Domain Anti-PD-L1 Antibody, in Patients with Advanced Solid Tumors. , 2021, The oncologist.

[7]  Jianwei Zhu,et al.  RPL21 siRNA Blocks Proliferation in Pancreatic Cancer Cells by Inhibiting DNA Replication and Inducing G1 Arrest and Apoptosis , 2020, Frontiers in Oncology.

[8]  K. Shah,et al.  Nanobodies: Next Generation of Cancer Diagnostics and Therapeutics , 2020, Frontiers in Oncology.

[9]  Jianwei Zhu,et al.  Generating a Novel Bispecific Nanobody to Enhance Antitumor Activity , 2020, Pharmaceutical Fronts.

[10]  Stephen M. Shaw,et al.  BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial , 2020, Nature Medicine.

[11]  Jianwei Zhu,et al.  A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer , 2020, Journal of experimental & clinical cancer research : CR.

[12]  Deshka S. Foster,et al.  Pancreatic Cancer Associated Fibroblasts (CAF): Under-Explored Target for Pancreatic Cancer Treatment , 2020, Cancers.

[13]  Jianwei Zhu,et al.  Construction of Novel Bispecific Single-Domain Antibodies (BiSdAbs) with Potent Antiangiogenic Activities , 2020, Pharmaceutical Fronts.

[14]  M. Karamouzis,et al.  Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy , 2020, World journal of gastrointestinal oncology.

[15]  S. A. van de Pavert,et al.  Deciphering the Crosstalk Between Myeloid-Derived Suppressor Cells and Regulatory T Cells in Pancreatic Ductal Adenocarcinoma , 2020, Frontiers in Immunology.

[16]  Yakun Wan,et al.  Blocking the PD-1-PD-L1 axis by a novel PD-1 specific nanobody expressed in yeast as a potential therapeutic for immunotherapy. , 2019, Biochemical and biophysical research communications.

[17]  S. Sakaguchi,et al.  Targeting Treg cells in cancer immunotherapy , 2019, European journal of immunology.

[18]  J-Pablo Salvador,et al.  Nanobody: outstanding features for diagnostic and therapeutic applications , 2019, Analytical and Bioanalytical Chemistry.

[19]  M. Smit,et al.  Nanobody‐Fc constructs targeting chemokine receptor CXCR4 potently inhibit signaling and CXCR4‐mediated HIV‐entry and induce antibody effector functions , 2018, Biochemical pharmacology.

[20]  Flora Peyvandi,et al.  Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura , 2019, The New England journal of medicine.

[21]  J. Gulley,et al.  Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy , 2018, Expert review of vaccines.

[22]  H. Kaufman,et al.  Integrating oncolytic viruses in combination cancer immunotherapy , 2018, Nature Reviews Immunology.

[23]  C. Fenselau,et al.  Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment , 2018, The Journal of Immunology.

[24]  Lianfang Zheng,et al.  PD-1/PD-L1 and immunotherapy for pancreatic cancer. , 2017, Cancer letters.

[25]  Tasuku Honjo,et al.  Cancer immunotherapies targeting the PD-1 signaling pathway , 2017, Journal of Biomedical Science.

[26]  Aiwu Zhou,et al.  Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade , 2017, Cell Discovery.

[27]  R. Vandenbroucke,et al.  Nanobodies as therapeutics: big opportunities for small antibodies. , 2016, Drug discovery today.

[28]  Gideon Blumenthal,et al.  FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy , 2016, The oncologist.

[29]  S. Na'ara,et al.  Gemcitabine resistance in pancreatic ductal adenocarcinoma. , 2015, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[30]  R. Jain,et al.  CXCR4 inhibition in tumor microenvironment facilitates anti‐programmed death receptor‐1 immunotherapy in sorafenib‐treated hepatocellular carcinoma in mice , 2015, Hepatology.

[31]  D. Fearon,et al.  T cell exclusion, immune privilege, and the tumor microenvironment , 2015, Science.

[32]  Caroline H. Diep,et al.  Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer , 2015, Clinical Cancer Research.

[33]  L. Kremer,et al.  Chemokine Receptor-Specific Antibodies in Cancer Immunotherapy: Achievements and Challenges , 2015, Front. Immunol..

[34]  J. Werner,et al.  Characterization of myeloid leukocytes and soluble mediators in pancreatic cancer: importance of myeloid-derived suppressor cells , 2015, Oncoimmunology.

[35]  Jianwei Zhu,et al.  Knockdown of ribosomal protein L39 by RNA interference inhibits the growth of human pancreatic cancer cells in vitro and in vivo. , 2014, Biotechnology journal.

[36]  D. Fearon.  The Carcinoma-Associated Fibroblast Expressing Fibroblast Activation Protein and Escape from Immune Surveillance , 2014, Cancer Immunology Research.

[37]  Derek S. Chan,et al.  Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer , 2013, Proceedings of the National Academy of Sciences.

[38]  P. Ascierto,et al.  Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. , 2012, The Lancet. Oncology.

[39]  E. D. de Vries,et al.  CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy. , 2012, Neoplasia.

[40]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[41]  D. Gabrilovich,et al.  Coordinated regulation of myeloid cells by tumours , 2012, Nature Reviews Immunology.

[42]  G. Dranoff,et al.  CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. , 2011, Cancer research.

[43]  R. Leurs,et al.  CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells , 2010, Proceedings of the National Academy of Sciences.

[44]  S. Rosenberg,et al.  Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma , 2010, Journal of immunotherapy.

[45]  C. Divino,et al.  Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. , 2006, Cancer research.

[46]  H. Sprong,et al.  The blood–brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells , 2005, Journal of neurochemistry.

[47]  Dennis C. Sgroi,et al.  Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion , 2005, Cell.

[48]  Serge Muyldermans,et al.  Efficient tumor targeting by single‐domain antibody fragments of camels , 2002, International journal of cancer.

[49]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[50]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[51]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.